Press release
Uterine Fibroids Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Uterine Fibroids Pipeline Drugs
Uterine fibroids are the most commonly seen non-cancerous tumors of the female reproductive system. The fibroids otherwise called leiomyomas, uterine myomas or fibromas. These are compact tumors which are made up of smooth muscle and fibrous connective tissue that develops in uterus.
Uterine fibroids most commonly found during routinepelvic examination. Smaller fibroids may not found during the normal examination, ultrasound examination may require. And physicians may suggest the diagnostic imaging techniques such as Ultrasound, saline infusion sonography, MRI or compound tomography for the detection of the fibroids in uterus.
Generally, uterine fibroids treatment may include minimally invasive procedures such as hysterectomy, myomectomy and uterine artery embolization. Gonadotropin-releasing hormones are used to lower the levels of estrogen and triggers “medical menopause” and sometimes these hormones shrink the fibroids and make surgical treatment easier. Painkillers may be used to reduce the pain.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/uterine-fibroids-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx
Segmentation:
Uterine fibroids pipeline drugs are segmented based on route of administration, trial phase,and company
By route of administration, uterine fibroids pipeline drugs are segmented into
• Oral
• Vaginal
• Others
By trial phase, uterine fibroids pipeline drugs are segmented into
• Pre-clinical phase
• Phase-I
• Phase II
• Phase-III
By company, uterine fibroids pipeline drugs are segmented into
• Repros Therapeutics Inc. (U.S.)
• Bayer AG (Germany)
• Takeda Pharmaceutical Company Ltd (Japan)
• AbbVie Inc. (U.S.)
• KISSEI PHARMACEUTICAL CO.,Ltd. (Japan)
• BioSpecifics Technologies Corporation (U.S.)
• DONGKOOK Pharmaceutical Co., Ltd (Japan)
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/uterine-fibroids-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu
Space Analysis:
• Bayer AG expected to start its late-stage clinical trials (phase-3) for novel prostaglandin receptor agonist, vilaprisan for the treatment of woman with uterine fibroids in Feb 2018.
• In October 2017, Takeda Pharmaceutical Company Limited announced that phase-3 clinical trials of its TAK-385, a gonadotropin-releasing hormone receptor agonist, met the primary endpoint of infertility to the active control group in the treatment of uterine fibroids in Japan. Furthermore, company is planning to submit results to regulatory authorities in Japan for marketing authorization of relugolix for treatment of uterine fibroids.
Report Description:
Uterine Fibroids Pipeline Drugs Assessment report studies the various therapeutics under clinical development for uterine fibroids treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the uterine fibroids pipeline drugsdevelopment. This report studies the dynamics of the Uterine Fibroids Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on uterine fibroids pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/uterine-fibroids-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3
Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis on each drug candidates in the clinical trial phases
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/uterine-fibroids-pipeline-drugs-assessment/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uterine Fibroids Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 here
News-ID: 1040132 • Views: …
More Releases from Precision Business Insights
Biochar Market Growth Is Attributed To The Increased Production Of Biochar Throu …
According to Precision Business Insights (PBI), the latest report biochar market was valued at USD 243.8 million in 2022, growing at a 12.6% CAGR during the forecast period 2023 to 2029. The rising demand for organic and eco-friendly products drives the biochar market. Utilizing biochar corresponds with organic farming methods, improving market prospects. Furthermore, biochar is a potential material for water treatment and remediation because of its capacity to absorb…
Vapor Recovery Units Market Growth Is Attributed To The Increased Adoption Of Me …
According to Precision Business Insights (PBI), latest report vapor recovery units market was valued at USD 923.7 million in 2022 and is poised to grow at a CAGR of 4.2% during the forecast period 2023 to 2029. The adoption of stringent environmental regulations by governments and international bodies to reduce air pollution and greenhouse gas emissions in various countries drives the demand for the vapor recovery unit's market. Furthermore, the…
Pyrite Market Growth Is Attributed To The Increased Demand In Jewelry Industry
According to Precision Business Insights (PBI), latest report pyrite market is growing at 4.9% CAGR during the forecast period 2023 to 2029. The increased application of pyrite in the manufacturing of sulfuric acid drives the pyrite market. The increase of prices of gold has led to increased demand for imitation jewelry which is anticipated to propel the pyrite market growth. Furthermore, the demand for sulphuric acid in a variety of…
Industrial Boilers Market Growth Is Attributed To The Increased Use In Power Gen …
According to Precision Business Insights (PBI), the latest report industrial boilers market size was valued at USD 15,261.8 million in 2022 and is poised to grow at a 3.1% CAGR during the forecast period 2023 to 2029. The adoption of stringent environmental regulations to maintain emission standards and carbon reduction in several countries drives the industrial boilers market. Furthermore, the advancement in boiler technology, such as better combustion systems, greater…
More Releases for Uterine
Uterine Manipulator Devices Market Report 2018: Segmentation by Type (Donnez Typ …
Global Uterine Manipulator Devices market research report provides company profile for ConMed, Richard Wolf, Bisinger, Planmeca Oy, Ethicon Endosurgery, Cooper Surgical, Hospiiniz International, C. R. Bard and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025,…
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018 - Research By Ma …
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers…
Uterine Leiomyoma (Uterine Fibroids) Market: Global Industry Size, Share, Growth …
Latest industry research report on: Global Uterine Leiomyoma Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts.
DelveInsight's,Uterine Leiomyoma (Uterine Fibroids)-Global API Manufacturers,Marketed and Phase III Drugs Landscape,2018" report provides comprehensive insights about marketed and Phase III products for Uterine Leiomyoma (Uterine Fibroids) . The report includes information of marketed products including their product description,patent details,forecasted sales till 2020 & API manufacturer details by country.
Global API…
Uterine Leiomyoma (Uterine Fibroids)-Drugs Analysis, Market Trends and Forecast …
The various complications of uterine leiomyoma such as discomfort and complications such as anemia from heavy blood loss require the early detection and proper medication. Varying environmental factors such as birth control; vitamin D deficiency; obesity; and drinking alcohol, including beer, appear to increase the risk of developing fibroids. To discuss the market insight in-depth, Market Research Hub (MRH) has lately added a research study titled as “Uterine Leiomyoma (Uterine…
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2017
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2017”. Uterine fibroids are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium.
Request For Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1246573
Uterine fibroids are usually round. The most common…
Uterine Fibroids Treatment Market: Rising Prevalence of Uterine Fibroids amongst …
The high prevalence of uterine fibroids across the U.S. has created a significant demand for uterine fibroid treatments across the countries. The growing public concern about the occurrence of uterine fibroids, which are also called uterine leiomyoma, have propelled the demand for treatments and solutions to alleviate the pain, excessive bleeding, and pelvic discomfort.
According to the report by Transparency Market Research, the U.S. uterine fibroid treatment market is anticipated to…
